UK the first European market to launch oral Wegovy
The United Kingdom has become the first European market to commence the commercial rollout of oral Wegovy. Following authorisation by the Medicines and Healthcare products Regulatory Agency on June 11, 2026, private healthcare providers began dispensing the once daily semaglutide tablet on July 6. The launch introduces a needle free alternative to the dominant injectable GLP-1 therapies, specifically targeting the…
Infographic: The rise of NHS GLP-1 drug prescription
This graph below shows the prescription of GLP-1 medications from shortly after prescription medication Liraglutide was approved for NHS use in specialist weight management services in England to the present day. While a number of access factors have pushed uptake historically, a combination of heightened awareness and the availability of tirzepatide has pushed adoption significantly. However, based on expenditures, it…
Novo Nordisk agrees weight loss price drop with US Administration
Denmark-based global chronic disease specialist Novo Nordisk has announced an agreement with the U.S. Administration to lower Wegovy and Ozempic prices across Medicare Part D, Medicaid and cash channels starting 2026. In exchange, Medicare will pilot obesity-drug coverage and the company gains a three-year tariff exemption. Management pegs the change at a low-single-digit drag on 2026 global sales growth but…